1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: 301-796-9721
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Liver Injury/Regeneration
You have full text access to this OnlineOpen article
Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases†
Article first published online: 9 DEC 2008
DOI: 10.1002/hep.22620
Copyright © 2008 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Brinker, A. D., Wassel, R. T., Lyndly, J., Serrano, J., Avigan, M., Lee, W. M. and Seeff, L. B. (2009), Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases. Hepatology, 49: 250–257. doi: 10.1002/hep.22620
- †
Potential conflict of interest: Allen Brinker, Ronald Wassel, Jenna Lyndly, and Mark Avigan are employed at U.S. Food and Drug Administration. Jose Serrano and Leonard B. Seeff are employed at the National Institutes of Health. William M. Lee has recently served as a consultant to Eli Lilly, Wyeth, and Fibrogen.
- ‡
fax: 301-796-9721
Publication History
- Issue published online: 28 DEC 2008
- Article first published online: 9 DEC 2008
- Manuscript Accepted: 28 AUG 2008
- Manuscript Received: 6 MAY 2008
References
- 1, . Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002; 22: 157–167.
- 2, , , , , , et al for the Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512–521.
- 3, . Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005; 42: 481–489.
- 4, . An evaluation of hepatic events associated with telithromycin (within Briefing Document, Division of Drug Risk Evaluation Office of Surveillance and Epidemiology, pages 23-50). Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1–00-index.htm. Accessed June 11, 2008.
- 5. Ketek (telithromycin) tablets. In: Physicians' Desk Reference. Montvale, NJ: Thomson PDR; 2005: 710–717.
- 6FDA Drug information on Ketek posted February 12, 2007. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01561.html. Accessed June 11, 2008.
- 7Medical Officer Safety Review of NDA 21-144:Telithromycin (Ketek), March 31, 2004. http://www.fda.gov/cder/foi/nda/2004/21-144_Ketek.htm. Accessed July 11, 2008.
- 8. Pre-approval efficacy and safety data. Presentation before FDA Advisory Committee, Silver Spring, MD, December 12, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1–00–index.htm. Accessed July 11, 2008.
- 9, , , , , . Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144: 415–420.
- 10, , , . Acute hepatitis attack after exposure to telithromycin. Clin Ther 2007; 29: 1725–1729.
- 11, . Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review. Am J Health-Syst Pharm 2008; 65: 37–41.
- 12. Introducing MEDWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765–2768.
- 13, . Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. Clin Pharmacol Ther 2002; 71: 99–102.
- 14
- 15, . Drug-induced liver injury: summary of a single topic clinical research conference. HEPATOLOGY 2006; 43: 618–631.
- 16, , , , , , et al., for the DILIN Study Group. Rationale, Design and Conduct of the Drug-Induced Liver Injury Network (DILIN) Prospective study. Drug Safety 2009; 32 (1).
- 17. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther 2006; 79: 521–528.
- 18. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20(Suppl C): C40–C44.
- 19, . An evaluation of spontaneous adverse drug reaction monitoring systems. Am J Med 1986; 81 (Suppl 5B): 49–55.
- 20, , , . The effects of media publicity on spontaneous adverse reaction reporting with mefloquine in the UK. Pharmacoepidemiol Drug Safety 1997; 6(Suppl 2): 32.
- 21, , . Ulcerogenicity of piroxicam: analysis of spontaneously reported data. BMJ 1987; 294: 147–150.
- 22
- 23. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007; 47: 513–539.
- 24, , , , , , et al., for the ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935–952.
- 25, , , . Troglitazone-induced liver failure: a case study. Am J Med 2003; 114: 299–306.
- 26, , , . Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002; 36: 1162–1167.
- 27, . Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990; 150: 215–216.
- 28, , , , , , et al., for the Spanish Group for the Study of Drug-Induced Liver Disease. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. HEPATOLOGY 2006; 44: 850–856.
- 29, . Toxic and drug-induced hepatitis. In: Schiff L, Schiff ER, eds. Diseases of the liver. 6th ed. Philadelphia: J. B. Lippincott, 1987: 591–668.
- 30, , , , , , et al. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119: 576–583.
- 31, . Fulminant hepatic failure associated with clarithromycin. Am J Gastroenterol 1996; 91: 394–395.
- 32, , , , , , et al. Fulminant hepatitis and fatal toxic epidermal necrolysis (Lyell disease) coincident with clarithromycin administration in an alcoholic patient receiving disulfiram therapy. Arch Intern Med 2002; 162: 474–476.
- 33, , , . Clarithromycin use preceding fulminant hepatic failure. Am J Gastroenterol 2002; 97: 489–490.
- 34, , , , , . Fulminant liver failure associated with clarithromycin. Ann Pharmacother 2003; 37: 57–60.
- 35, , , . Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004; 53: 149–157.
- 36, , . Antibiotic drug interactions. Med Clin North Am 2006; 90: 1223–1255.
- 37, . Telithromycin: the first ketolide antimicrobial. Clin Ther 2005; 27: 1144–1163.
- 38, , , , , , et al. Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment. Neurology 2006; 67: 2256–2258.
- 39. Vision disorders, disturbances in consciousness, and exacerbations of myasthenia gravis. Presentation before FDA Advisory Committee, Silver Spring, MD, December 12, 2006. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1–00–index.htm. Accessed June 11, 2008.
- 40, , . Apparent anaphylactoid reaction after treatment with a single dose of telithromycin. Ann Allergy Asthma Immunol 2007; 98: 89–91.
- 41, . Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–1330.
- 42, , . Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331–1336.
- 43. Use and limitations of the RUCAM. AASLD-FDA-NIH-PhRMA- Hepatotoxicity Steering Group Meeting, Bethesda MD, January 25-26, 2006. Slide presentation available at: http://www.fda.gov/CDER/livertox/presentations2006/Freston.pdf. Accessed August 22, 2008.
- 44, , , , , , et al., for the Drug Induced Liver Injury Network. The reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. HEPATOLOGY 2008; 48(4): 1175–1183.